GPC3 and hepatocellular carcinoma: The specific expression patterns of GPC‐3 protein and PD‐L1 mRNA might vary due to differences in HCC subtype, disease stage, and individual patient characteristics.[61] Nevertheless, the GPC‐3 protein has emerged as a potential highly specific target for HCC,[62] while ≈25% of HCC cases are found to have high levels of PD‐L1 expression,[63] a typical marker for tumor immunotherapy.